Cemiplimab Biosimilar, Anti-human PD-1 Monoclonal Antibody | C029P

Catalog No.	C029P
Product Name	Cemiplimab Biosimilar, Anti-human PD-1 Monoclonal Antibody | C029P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	programmed cell death protein 1, PD1, CD279, cluster of differentiation 279
Summary	Recombinant Humanized IgG4 Monoclonal Antibody.
Source/Host	The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody cemiplimab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade cemiplimab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by cemiplimab.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade cemiplimab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Cemiplimab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C029P: Cemiplimab Biosimilar, Anti-human PD-1 Monoclonal Antibody

Recombinant Humanized IgG4 Monoclonal Antibody.

Background

Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab.

PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).

Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system’s anti-tumor response.

Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.

Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins:
Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody

PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
In vivo grade recombinant anti-mouse PD1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)

Please remember our product information: Cemiplimab Biosimilar, PD-1 Monoclonal Antibody: C029P Syd Labs

No more offers for this product!